Donanemab: The Breakthrough Drug Ushering a New Era in Alzheimer’s Treatment
Share This Story
A new Alzheimer's drug, Donanemab shows a 35% slowdown in cognitive decline.
It is anticipated that the FDA is about to approve a third new Alzheimer’s drug, Donanemab. The drug showed a 35% slowdown in cognitive decline in certain patients. To learn more about this drug and who can benefit, read the full article in SciTech Daily, click here.
About the Author: Gary Skole
